casirivimab/imdevimab

{
  "id": "MLC-T-ONC-012330",
  "term": "casirivimab/imdevimab",
  "field": "Oncology and biomedicine",
  "definition": "A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.",
  "synonyms": [
    "anti-COVID cocktail REGN-COV2",
    "anti-Spike SARS-CoV-2 monoclonal antibodies REGN-COV2",
    "casirivimab and imdevimab",
    "casirivimab plus imdevimab",
    "REGN10933 plus REGN10987",
    "REGN10933+REGN10987",
    "SARS-CoV-2-specific antibodies REGN10933 and REGN10987",
    "casirivimab+imdevimab",
    "REGN10933/REGN10987"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/casirivimab-imdevimab/"
}